Patients with clinical suspicion or possible primary or recurrent malignant tumors (such as gliomas, liver cancer, gastric cancer, duodenal cancer, colorectal cancer, ovarian cancer and other malignancies prone to false-negative or false-positive results with 18F-FDG)
Conditions
Interventions
Gold Standard:The diagnosis is confirmed through pathological or clinical diagnostic treatments. Pathological confirmation methods include: biopsy by puncture, laparoscopy, and open abdominal explorat
Sponsors
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Patients with clinical suspicion or exclusion of primary or recurrent malignant tumors (such as glioma of the brain, liver cancer, gastric cancer, duodenal cancer, colorectal cancer, ovarian cancer etc, where 18F-FDG is prone to false negatives and false positives); 2.Patients undergoing tumor staging or evaluating treatment effect using 18F-FDG PET/CT or 18F-FGln PET/CT to determine the most appropriate treatment strategy; 3.Patients without other tumor history; 4.Patients with good compliance, providing informed consent, and able to follow the research protocol;
Exclusion criteria
Exclusion criteria: 1.pregnant or lactating patients or patients under 18 years old; 2.the subjects and their parents or legal representatives are unable or unwilling to provide written informed consent; 3.patients with poor compliance, unable to tolerate or cooperate with PET/CT examinations. 4.those who have undergone gastrointestinal barium meal examination within one week; 5.other situations where the investigators consider it inappropriate for the subjects to participate in this clinical trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TBR;SUVmax;accuracy;sensibility;specificity; | — |
Countries
China
Contacts
Public ContactZhang Rusen
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Outcome results
None listed